NLRP3 and liver disorder: NLRP3 inflammasome-induced cytokines release and pyroptosis processes are the key inflammatory targeting signals in liver disease; therefore, medicines involved in the regulation of the NLRP3 inflammasome represent the primary therapeutic approach for NAFLD management.